1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 119 pages

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastroesophageal (GE) Junction Carcinomas and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015
Table of Contents
Introduction 7
Global Markets Direct Report Coverage 7
Gastroesophageal (GE) Junction Carcinomas Overview 8
Therapeutics Development 9
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview 9
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis 10
Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies 11
Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies 15
Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development 16
Amgen Inc. 16
Aslan Pharmaceuticals Pte. Ltd. 17
AstraZeneca PLC 18
Basilea Pharmaceutica AG 19
Bristol-Myers Squibb Company 20
Celltrion, Inc. 21
Exelixis, Inc. 22
F. Hoffmann-La Roche Ltd. 23
Gilead Sciences, Inc. 24
Merck and Co., Inc. 25
Merck KGaA 26
Merrimack Pharmaceuticals, Inc. 27
Ono Pharmaceutical Co., Ltd. 28
Taiho Pharmaceutical Co., Ltd. 29
Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(tegafur + gimeracil + oteracil) - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
avelumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
BAL-101553 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
cabozantinib s-malate - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
DKN-01 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
gefitinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
GS-5745 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
ipilimumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
MK-2206 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
MM-111 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
nimotuzumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
nivolumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
pertuzumab - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
SNX-5422 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
trastuzumab biosimilar - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
trebananib - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
varlitinib - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
Gastroesophageal (GE) Junction Carcinomas - Recent Pipeline Updates 82
Gastroesophageal (GE) Junction Carcinomas - Dormant Projects 115
Gastroesophageal (GE) Junction Carcinomas - Discontinued Products 116
Gastroesophageal (GE) Junction Carcinomas - Product Development Milestones 117
Featured News and Press Releases 117
Sep 19, 2014: Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on MM-111 at the ESMO 2014 Congress 117
Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University 117
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 118
Disclaimer 119

List of Tables

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H1 2015 9
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H1 2015 16
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 17
Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca PLC, H1 2015 18
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Basilea Pharmaceutica AG, H1 2015 19
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H1 2015 20
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Celltrion, Inc., H1 2015 21
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Exelixis, Inc., H1 2015 22
Gastroesophageal (GE) Junction Carcinomas - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 23
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Gilead Sciences, Inc., H1 2015 24
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck and Co., Inc., H1 2015 25
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck KGaA, H1 2015 26
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 27
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 28
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Assessment by Combination Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H1 2015 82
Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H1 2015 115
Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H1 2015 116

List of Figures

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 14
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Top 10 Targets, H1 2015 32
Number of Products by Stage and Top 10 Targets, H1 2015 32
Number of Products by Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Top 10 Routes of Administration, H1 2015 36
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36
Number of Products by Top 10 Molecule Types, H1 2015 38
Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

Prescription barriers hurt 5 of the 9 brands we surveyed. Is your brand losing market share? In the EU5, one of the most prescribed NSCLC drugs is stuck in 2nd place due to the biggest barrier-related ...

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the UK

  • November 2016
    10 pages
  • Cancer  

  • United Kingdom  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.